Jiménez-Romero Carlos, Marcacuzco Quinto Alberto, Manrique Municio Alejandro, Justo Alonso Iago, Calvo Pulido Jorge, Cambra Molero Félix, Caso Maestro Óscar, García-Sesma Álvaro, Moreno González Enrique
Unidad de Cirugía Hepato-Bilio-Pancreática y Trasplante de Órganos Abdominales, Departamento de Cirugía, Hospital Universitario Doce de Octubre, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, España.
Unidad de Cirugía Hepato-Bilio-Pancreática y Trasplante de Órganos Abdominales, Departamento de Cirugía, Hospital Universitario Doce de Octubre, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, España.
Cir Esp (Engl Ed). 2018 Jan;96(1):25-34. doi: 10.1016/j.ciresp.2017.09.016. Epub 2017 Oct 28.
Simultaneous pancreas-kidney transplantation (SPKT) constitutes the therapy of choice for diabetes type1 or type2 associated with end-stage renal disease, because is the only proven method to restore normo-glicemic control in the diabetic patient.
Retrospective and descriptive study of a series of 175 patients who underwent SPKT from March 1995 to April 2016. We analyze donor and recipient characteristics, perioperative variables and immunosuppression, post-transplant morbi-mortality, patient and graft survival, and risk factors related with patient and graft survival.
Median age of the donors was 28years and mean age of recipients was 38.8±7.3years, being 103 males and 72 females. Enteric drainage of the exocrine pancreas was performed in 113 patients and bladder drainage in 62. Regarding post-transplant complications, the overall rate of infections was 70.3%; graft pancreatitis 26.3%; intraabdominal bleeding 17.7%; graft thrombosis 12.6%; and overall pancreas graft rejection 10.9%. The causes of mortality were mainly cardiovascular and infectious complications. Patient survival at 1, 3 and 5-year were 95.4%, 93% and 92.4%, respectively, and pancreas graft survival at 1, 3 and 5-year were 81.6%, 77.9% y 72.3%, respectively.
In our 20-year experience of simultaneous pancreas-kidney transplantation, the morbidity rate, and 5-year patient and pancreas graft survivals were similar to those previously reported from the international pancreas transplant registries.
胰肾联合移植(SPKT)是1型或2型糖尿病合并终末期肾病的首选治疗方法,因为它是唯一经证实能使糖尿病患者恢复正常血糖控制的方法。
对1995年3月至2016年4月期间接受SPKT的175例患者进行回顾性描述性研究。我们分析了供体和受体的特征、围手术期变量和免疫抑制情况、移植后发病率和死亡率、患者和移植物存活率以及与患者和移植物存活相关的危险因素。
供体的中位年龄为28岁,受体的平均年龄为38.8±7.3岁,其中男性103例,女性72例。113例患者采用胰外分泌腺肠道引流,62例采用膀胱引流。关于移植后并发症,感染总发生率为70.3%;移植胰腺炎为26.3%;腹腔内出血为17.7%;移植血栓形成率为12.6%;胰腺移植物总体排斥率为10.9%。死亡原因主要是心血管和感染并发症。患者1年、3年和5年生存率分别为95.4%、93%和92.4%,胰腺移植物1年、3年和5年生存率分别为81.6%、77.9%和72.3%。
根据我们20年的胰肾联合移植经验,发病率以及患者和胰腺移植物5年生存率与国际胰腺移植登记处先前报告的结果相似。